Aslan Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
ASLN Aslan Pharmaceuticals Ltd
WYND Wyndham Destinations Inc
GRWWF Great Wall Pan Asia Holdings Ltd
BAC Bank of America Corp
FULC Fulcrum Therapeutics Inc
T AT&T Inc
F Ford Motor Co
JNJ Johnson & Johnson
HHER Her Imports
WSBF Waterstone Financial Inc

Health Care : Biotechnology | Small Cap Value
Based in Singapore
Company profile

ASLAN Pharmaceuticals Limited is a clinical-stage oncology and immunology focused biopharmaceutical company. The Company’s portfolio is comprised of one monoclonal antibody therapy targeting inflammatory disease and two small molecule inhibitors targeting oncology. The Company’s products include ASLAN004, ASLAN003 and Varlitinib. ASLAN004 is a fully human monoclonal antibody that binds to the IL-13 receptor alpha1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. ASLAN003 is an inhibitor of human dihydroorotate dehydrogenase (DHODH), in acute myeloid leukemia (AML) and are exploring development in other solid tumors. Varlitinib is an oral, reversible small-molecule pan-HER inhibitor.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

UPDATE: As bleak COVID-19 headlines mount, investors worry only about the facts 'they can live with,' analyst says

9:57 am ET July 28, 2020 (MarketWatch)

By Shawn Langlois, MarketWatch

'Investors seem still caught in a past-tense, future-perfect kind of mood'

The stock market has a lot to navigate this week, from the daily dose of coronavirus gloom to a hefty lineup of earnings, including huge names like Apple(AAPL) , Amazon(AMZN) , Alphabet(GOOGL) , Exxon Mobil(XOM)and Pfizer(PFE) .

But if investors are worried about getting caught wrong-footed, you wouldn't know it from this chart from Qontigo, which shows that they are "uncharacteristically positive in the face of rising uncertainty about the economic rebound in the second half of the year":

The chart shows Qontigo's recently created ROOF score, an acronym that stands for "risk-on/risk-off." It's basically a gauge of how bullish investor are at any given moment.

As you can see, bullishness is currently running high.

"Investors seem still caught in a past-tense, future-perfect kind of mood having decided that they should not worry about all the facts, only those they can live with," Qontigo analysts wrote in a note this week about the divergence between market performance and fundamentals.

In their view, quantitative easing is trumping the presumption of economic fragility.

"The second wave of new infections is threatening large swath of the global economy and raising the probability of second lockdowns," the analysts wrote. "But like the mother of a drug dealer, or the neighbor of a serial killer, investors seem to be the last to know, preferring instead to focus on the stimulus packages this will invite." So it's "BUY, BUY, BUY!" regardless.

Bottom line: The consensus, according to Qontigo, is that even if the big earnings lineup doesn't support the current valuations, easy money from the Fed and/or a new stimulus package will.

"Risk tolerance continues to rise and risk-aversion decline, despite a worsening COVID-19 narrative as investors recreate their own 'fuggedaboutit' moment," the analysts said.

Meanwhile, the bulls took a bit of a hit in Tuesday's trading session, with the Dow Jones Industrial Average , S&P 500and tech-heavy Nasdaq Compositeall moving into the red early.

-Shawn Langlois; 415-439-6400;

(END) Dow Jones Newswires

July 28, 2020 09:57 ET (13:57 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.